FDA Investigator Geoffrey K Kilili

Geoffrey K Kilili has inspections in 7 countries as of 27 Oct 2023. Geoffrey K Kilili has collaborated with a combinined 2584 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
76
Last Inspection Date:
27 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
Georgia, United States of America, India, Argentina, Latvia, Hungary, Peru
Co-Investigator(s):
A Williams, Alanna Lmussawwir Bias, Allen F Hall, Allison C Hunter, Amanda E Lewin, PhD, Andrew J Barrowcliff, Andria L Kuhlman, Anna M Brannen, Annette Melendez, Arindam Dasgupta, PhD, Audria L Kuhlman, Barbara A Rusin, Barbara M Frazier, Barbara M Frezior, Brandy D Brown, Brittany M Kershaw, Carol Mrivera Lopez, PhD, Cassandra L Winters, Cheryl A Grandinetti, Ching Jeyg Chang, Christina L Bigham, Christopher T Middendorf, Cooper Cooper, Karen M, Corrine M Carter, Courtney N Long, Craig T Rybus, Cynthia F Kleppinger, MD, Cynthia L Rakestraw, Cynthia T Cain, D'arbra R Blankenship, Daniel L Aisen, David L Chon, Dell S Moller, Demitria J Xiradakis, Dr. Abhijit Raha, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Dylin Yao, Fatima Bassa, Felicia E Hinojosa, Gary J Hagan, Gene D Arcy, Gene R Gunn, Gilbert J Heidenblut, Gregson A Joseph, Gulshan R Anand, Harperd, Hasan A Irier, PhD, High M Mcclure, III, Hugh M Mcclure, II, Hyojong Kwon, PhD, Jacqueline S Warner, James R Fleckenstein, Jane M Kreis, Janet L Bowen, Janete F Guardia, Javonica F Penn, Jennifer C Adams, Jennifer L Jager, Jennifer L Sheehan, John A Kadavil, PhD, John Dan, Joseph L Despins, PhD, Jyoti B Patel, PhD, Ka L Wong, Kara A Scheibner, PhD, Karen M Cooper, Karen M Kondas, Kathleen D Culver, Kathryn Suttling, Keith J Mason, Kelli Wilkinson, Kilili Kilili, Geoffrey K, Kimberley A Ricketts, Kimberly A Joseph, Kip J Hanks, Kirk A Dymbrowski, Kirtida Patel, Klein, L Gnnmassimia Massimilla, PharmD, Laine P Myers, Lakecha N Lewis, Laura E Garcia, Laureen M Geniusz, Lauren N Howard, Leslie R Clark, Li Hongpaul Yeh, PhD, Lianji Jin, Linda R Kuchenthal, Lindsey M Schwierjohann, Lisa R Hilliar, Lori A Gioia, Luann Mckinney, Marcia A Worley, Mark E Parmon, Matthew B Casale, Matthew C Watson, Matthew J Gretkierewicz, Michael E Campbell, Michael G Mayfield, Michael P Anthony, Michele L Glendenning, Mike M Rashti, Mishelle L Harriger, Mpris Inspector, Nancy L Neiger, Nicholas L Paulin, Nutan Mytle, Paul E Stein, Paula J Bretz, Phillip M Pontikos, Pifer, Rebecca Rodriguez, Rebecca T Davis, Richard W Berning, Rosanna M Goodrich, Ruben C Ayala, PharmD, Sam Pepe, Scott B Laufenberg, Srlram Subramaniam, PhD, State Agency, Stephen J Kilker, Susan D Yuscius, Susanne M Richardson, MSc RAC ELS, Tamara M Kays, Teresa K Kastner, Thea C Grome, Thomas W Nojek, Thunder N Dunkijacobs, Timothy C Grome, Tracey L Harris, Ucheabuchi C Chudi Nwankwor, Victoria M Daddeo, Wr Bowman, Yiying E Chen, Yiyue Zhang (nmi), PhD, Young M Choi, PhD, Young M Yoon, Yvette Mlacour Davis

Geoffrey K Kilili's Documents

Publish Date Document Type Title
September, 2021 EIR Agios Pharmaceuticals, INC. - EIR, 2021-09-24
July, 2021 EIR Axsome Therapeutics, Inc. - EIR, 2021-07-15
January, 2017 EIR Davis Remington Inc - EIR, 2017-01-27
October, 2020 EIR Charles River Laboratories Inc - EIR, 2023-10-17
January, 2021 FDA 483 Sameek Roychowdhury, MD - Form 483, 2021-01-22
December, 2018 EIR AtriCure, Inc. - EIR, 2018-12-13
September, 2022 FDA 483 Martin T. Taylor, DO, PhD - Form 483, 2022-09-30
March, 2019 EIR Nationwide Children's Hospital IRB - EIR, 2019-03-11
October, 2017 EIR Ronald F. Budzik Jr., MD - EIR, 2017-10-17
February, 2017 EIR Samir Arora, MD - EIR, 2017-02-17
February, 2021 FDA 483 Sagar Sardesai, M.D. - Form 483, 2021-02-12
April, 2017 EIR Battelle Memorial Institute - EIR, 2017-04-21
July, 2017 EIR Cleveland Medical Devices Inc - EIR, 2017-07-07
September, 2023 FDA 483 Safecor Health, LLC - Form 483, 2023-09-01
February, 2018 EIR Jaglowski, Samantha - EIR, 2018-02-14
October, 2017 FDA 483 Ronald F. Budzik Jr., MD - Form 483, 2017-10-17
July, 2017 FDA 483 Cleveland Medical Devices Inc - Form 483, 2017-07-07
March, 2018 FDA 483 Sergio D. Bergese - Form 483, 2018-03-30
October, 2017 FDA 483 Response Ronald F. Budzik Jr., MD - Form 483R, 2017-11-27
July, 2017 FDA 483 Response Cleveland Medical Devices Inc - Form 483R, 2017-07-07
January, 2017 FDA 483 Davis Remington Inc - Form 483, 2017-01-27
June, 2018 FDA 483 Michael Racke MD - Form 483, 2018-06-15
September, 2019 FDA 483 Jennifer Woyach, M.D. - Form 483, 2019-09-03
May, 2017 EIR Nationwide Children's Hospital IRB - EIR, 2017-05-26
December, 2017 FDA 483 Shivkamini Somasundaram, M.D. - Form 483, 2017-12-18
November, 2019 EIR Battelle Memorial Institute - EIR, 2019-11-08
August, 2018 EIR Charles River Laboratories Ashland, LLC - EIR, 2018-08-03
January, 2018 FDA 483 David O'Malley, MD - Form 483, 2018-01-23
February, 2018 FDA 483 Jaglowski, Samantha - Form 483, 2018-02-14
August, 2021 FDA 483 AmplifyBio, LLC. - Form 483, 2021-08-05
August, 2021 FDA 483 Battelle Memorial Institute - Form 483, 2021-08-05
February, 2017 FDA 483 Samir Arora, MD - Form 483, 2017-02-17
July, 2023 FDA 483 American Regent, Inc. - Form 483, 2023-07-20
October, 2019 FDA 483 Mount Carmel Health System IRB - Form 483, 2019-10-29
June, 2023 FDA 483 Vantage Specialty Ingredients, Inc. - Form 483, 2023-06-27
October, 2023 FDA 483 Novartis Manufacturing LLC - Form 483, 2023-10-27
November, 2023 FDA 483 Amgen Inc. - Form 483, 2023-11-30

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.


Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more